These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23979793)

  • 1. Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.
    Harshman LC; Taplin ME
    Adv Ther; 2013 Aug; 30(8):727-47. PubMed ID: 23979793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
    Ohlmann CH; Jäschke M; Jaehnig P; Krege S; Gschwend J; Rexer H; Stöckle M
    Trials; 2017 Oct; 18(1):457. PubMed ID: 28978327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.
    Hoy SM
    Drugs; 2013 Dec; 73(18):2077-91. PubMed ID: 24271422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Boissier E; Loriot Y; Vignot S; Massard C
    Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
    Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
    Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
    Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C; Jimeno A; Kessler ER
    Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
    Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
    Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
    Scott LJ; Yang LPH; Lyseng-Williamson KA
    Drugs Aging; 2012 Mar; 29(3):243-248. PubMed ID: 22372727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C; Mourey L; Pouessel D; Ploussard G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
    Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
    Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
    Scott LJ
    Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.